Setback for AstraZeneca checkpoint inhibitor in US bladder cancer treatment
AstraZeneca is voluntarily withdrawing the use of its cancer drug, Imfinzi, to treat advanced bladder cancer in the US after it did not meet post-approval requirements.
AstraZeneca is voluntarily withdrawing the use of its cancer drug, Imfinzi, to treat advanced bladder cancer in the US after it did not meet post-approval requirements.
Pfizer and BioNTech have submitted new stability data to the US Food and Drug Administration (FDA), showing that their vaccine can be stored at standard freezer temperatures for two weeks.
Pfizer and BioNTech have dosed the first participants in a Phase 2/3 study for their COVID-19 vaccine in pregnant women; and plan to trial the vaccine in children later this year.
Celltrion’s adalimumab biosimilar, Yuflyma (CT-P17) has been approved by the European Commission for the treatment of multiple chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis.
The UK government has announced the launch of the Advanced Research and Invention Agency (ARIA), an initiative to fund “high-risk, high-reward” scientific research in the hope of achieving “groundbreaking” discoveries.